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Mitochondrial quality control is fundamental to all neurodegenerative diseases, including the most prominent ones,
Alzheimer’s Disease and Parkinsonism. It is accomplished by mitochondrial network dynamics – continuous fission
and fusion of mitochondria. Mitochondrial fission is facilitated by DRP1, while MFN1 and MFN2 on the
mitochondrial outer membrane and OPA1 on the mitochondrial inner membrane are essential for mitochondrial
fusion. Mitochondrial network dynamics are regulated in highly sophisticated ways by various different
posttranslational modifications, such as phosphorylation, ubiquitination, and proteolytic processing of their key-
proteins. By this, mitochondria process a wide range of different intracellular and extracellular parameters in order
to adapt mitochondrial function to actual energetic and metabolic demands of the host cell, attenuate
mitochondrial damage, recycle dysfunctional mitochondria via the mitochondrial autophagy pathway, or arrange
for the recycling of the complete host cell by apoptosis. Most of the genes coding for proteins involved in this
process have been associated with neurodegenerative diseases. Mutations in one of these genes are associated
with a neurodegenerative disease that originally was described to affect retinal ganglion cells only. Since more and
more evidence shows that other cell types are affected as well, we would like to discuss the pathology of
dominant optic atrophy, which is caused by heterozygous sequence variants in OPA1, in the light of the current
view on OPA1 protein function in mitochondrial quality control, in particular on its function in mitochondrial fusion
and cytochrome C release. We think OPA1 is a good example to understand the molecular basis for mitochondrial
network dynamics.
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Mitochondrial dynamics become more and more im-
portant since it is recognized that the morphology of
this highly dynamic network is relevant for many patho-
logical conditions, foremost neurodegeneration [1] but
also stroke [2] and cancer [3,4]. Mitochondrial network
dynamics – continuous fission and fusion of mitochon-
dria – mediates mitochondrial quality control (MQC)
for the eukaryotic cell. MQC comprises more than one
would initially associate with the term keeping mito-
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distribution, and reproduction in any mediumdamaged organelles. But mitochondria are capable to
process a wide range of different intracellular and extracel-
lular parameters by mitochondrial network dynamics and
they do this to accommodate cell homeostasis and cell
fate by the following measures: a) Mitochondrial network
morphology changes to either a more filamentous or more
fragmented state to adapt mitochondrial function to actual
energetic and metabolic demands of the host cell [5,6]. b)
Fusion of dysfunctional mitochondria to functional mito-
chondria can attenuate damage to mitochondrial proteins,
lipids, and mtDNA [7]. c) Inhibition of mitochondrial fu-
sion targets single dysfunctional mitochondria to the mito-
chondrial autophagy pathway [8]. And most importantly d)
Mitochondrial fragmentation, mitochondrial outer mem-
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mitochondrial ontology is referred to as MQC and it is me-
diated by mitochondrial network dynamics. The mitochon-
drial network is regulated in highly sophisticated ways by
various different posttranslational modifications, such as
phosphorylation, ubiquitination, and proteolytic processing
of its key-proteins, which also reflects the wide range of
different intracellular and extracellular parameters inte-
grated into the MQC [1,10,11]. Mitochondrial fission is fa-
cilitated by DRP1 [10], while MFN1 and MFN2 on the
mitochondrial outer membrane, and OPA1 on the mito-
chondrial inner membrane are essential for mitochondrial
fusion [1]. Mutations in most of the genes encoding MQC
proteins have been associated with neurodegenerative dis-
eases with tremendous effects on the whole organism
(reviewed in [11] among others). Mutations in one of these
genes, however, are associated with a neurodegenerative
disease that originally was described to affect only the ret-
inal ganglion cells, which connect the eye via the optic
nerve to the brain. Though it is becoming more and more
evident that other cell types are affected as well. In the fol-
lowing we would like to discuss the pathology of dominant
optic atrophy (DOA; OMIM: #165500) caused by hetero-
zygous sequence variants in optic atrophy gene 1 (OPA1;
OMIM: *605290) in the light of the function of OPA1 in
MQC. We think OPA1 is a good example to understand
the molecular basis for MQC – the decision process be-
tween cell maintenance, mitochondrial autophagy, and cell
death. We would like to point out, as mentioned above,
that this represents only one part of mitochondrial net-
work regulation among many and that we are just at the
beginning of unraveling the complexity of this newly emer-
ging field of MCQ.
Dominant optic atrophy (DOA)
Neuropathies of the nervus opticus severely impair vision.
One can distinguish between acquired optic neuropathies,
which are mostly caused by intoxications (e.g. methanol,
cyanide, lead, chloramphenicol, ethambutol) or nutritional
deficiency symptoms (e.g. Vitamin B), and hereditary optic
neuropathies, which can be further subdivided into syn-
dromic forms with associated extra-ocular symptoms or
non-syndromic forms limited to the ocular phenotype
[12]. The two most common non-syndromic hereditary
optic neuropathies are DOA with an estimated prevalence
from 1:50 000 to 1:12 000 [13,14] and Leber’s hereditary
optic neuropathy (LHON; OMIM: #535000). DOA is also
referred to as optic atrophy, Kjer type (OAK) or juvenile
optic atrophy in older publications. DOA is associated
with mutations in nuclear genes encoding mitochondrial
proteins, primarily the OPA1 gene [15,16], while LHON is
associated with mutations in the remnant endosymbiotic
genome, the mitochondrial DNA (mtDNA). Noteworthy,
also acquired optic neuropathies involve mitochondrialimpairments (cf. [17]). Glaucoma, the leading cause of
worldwide blindness, is a non-syndromic optic neuropathy
of the elderly and a complex disease associated with both
environmental and genetic risk factors [18].
Patients with DOA suffer from slow progressive course
of painless bilateral visual function loss with onset typically
within the first two decades of life. The symptoms are
mild to severe decrease in visual acuity, color vision defi-
ciency, and visual field defects [19,20]. DOA is caused by
loss of retinal ganglion cells only (RGCs) located in the
inner retina and projecting their axons via the optic nerve
to the brain. RGC loss and atrophy of the optic nerve are
accompanied by thinning of the nerve fiber layer of the
retina and the characteristic fundus with pallor of the
optic disc [20,21], which is the structure where the RGC
axons exit the eye. RGCs are the only affected cells among
the 60 different neuronal cell types found in the retina and
although photoreceptors are the cells with the highest
oxygen consumption in the retina, light perception and
signal processing in the retina is not impaired but signal
transmission from the eye to the brain is distorted (see
[22] and references therein). The clinical presentation of
DOA is heterogeneous. The ocular phenotype is variable
and not all family-members that carry pathogenic muta-
tions in DOA associated genes present visual impairments
[19-21,23-26]. The probability for mutation carriers to de-
velop symptoms during lifetime has been estimated at
88% [26]. On the other hand, heterozygous OPA1 muta-
tions are associated with a broad range of extra-ocular
symptoms, sometimes at the sub-clinical level. These
symptoms include sensorineural deafness, ataxia, axonal
sensory-motor polyneuropathy, chronic progressive exter-
nal ophthalmoplegia, and mitochondrial myopathy
[27-31]. Some studies therefore differentiate between non-
syndromic and syndromic forms of DOA and suggest the
later being associated with dominant-negative OPA1 mu-
tations [30,32]. However, one can observe the whole
spectrum of disease manifestation from unaffected, to
non-syndromic, to syndromic patients within one family
segregating one single OPA1mutation [28,29]. This speaks
more for a continuous clinical picture of DOA rather than
a discrete one: different cell types are differently affected
in different individuals with RGCs being mainly affected.
Optic atrophy gene 1 (OPA1)
The human OPA1 gene is composed of 30 coding exons
(exon 1 to 28, exon 4b, exon 5b) distributed across more
than 90 kb of genomic DNA on chromosome 3q28-q29.
Alternative splicing of exons 4, 4b and 5b leads to eight
isoforms with open reading frames for polypeptides of 924
to 1015 amino acids [33]. The OPA1 proteins are classified
as large GTPases of the dynamin family, which are
imported into mitochondria by their amino-terminal im-
port sequence, and which are necessary for mitochondrial
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ants that cover the whole locus, OPA1 is the most fre-
quently mutated gene in DOA [34,35]. Mutations in
OPA1 account for at least 45% of all DOA cases and gen-
omic rearrangements in the OPA1 locus account for not
less than an additional 10% of DOA cases [23,36].
OPA1 is ubiquitously expressed and well conserved from
yeast to man, which underpins its fundamental biological
role. Genetic mouse- and fly-models that carry homozy-
gous OPA1 mutations show embryonic lethality [37,38],
but OPA1-null mouse embryonic fibroblasts can be cul-
tured [39], which suggests an essential function of mito-
chondrial inner membrane fusion during development
[40]. Only very few patients carry confirmed compound
heterozygous OPA1 mutations, a 30-year-old woman
(p.[E270K];[R290W]), who suffers from a severe ocular
manifestation of DOA [41], a 60-year-old man and his 64-
year-old sister (p.[S256R];[Q285R]), who both show ataxia,
myopathy, peripheral neuropathy, and spasticity in addition
to optic atrophy [42], an 8-year-old boy and his 3-year-old
sister (p.[I382M];[V903Gfs*3]), who show severe optic at-
rophy already at this young age and severe neurological
impairments with hypotonia and ataxia [43], and a 4-year-
old boy (p.[S64fs];[V377I]), who also shows severe ocular
phenotype already at this young age [44].
The OPA1 protein is associated with different func-
tions, such as maintenance of the respiratory chain and
membrane potential [45], cristae organization and con-
trol of apoptosis [46], as well as mitochondrial DNA
maintenance [30,31,47]. And yet, all studies agree in the
fact that OPA1 on the mitochondrial inner membrane,
together with MFN1 and MFN2 on the mitochondrial
outer membrane, is necessary for mitochondrial fusion
and that this process is regulated by proteolytic cleavage
of OPA1. Mitochondrial fusion in general requires both
long OPA1 isoforms (OPA1L) and short OPA1 isoforms
(OPA1S) [39], but the long OPA1L isoform alone is
sufficient for stress-induced mitochondrial fusion [48].
Many different proteases directly or indirectly lead
to OPA1 processing [39,49-54], among them are the
matrix– and the intermembrane space ATPases associ-
ated with a number of cellular activities (m-AAA and i-
AAA protease, respectively), the presenilin-associated
rhomboid-like protease (PARL), the high temperature
requirement A2 protease (HTRA2) and overlapping ac-
tivity with m-AAA protease (OMA1), which all are asso-
ciated with neurodegenerative diseases (reviewed in
[11]). Of note, heterozygous mutations in spastic para-
plegia gene 7 (SPG7; OMIM 602783), which codes for
paraplegin, one of two monomers that assemble m-AAA
proteases, have been identified in a four-generation fam-
ily segregating non-syndromic DOA with no signs of
spasticity, which is originally associated with mutations
in SPG7 [55].Our current understanding of OPA1 processing is that
OPA1 is translated in the cytosol and subsequently
imported into mitochondria, where it is processed by the
mitochondrial processing peptidase, which cleaves off the
amino-terminal import sequence after amino acid position
87 (NP_056375) [51]. These long OPA1L isoforms are an-
chored to mitochondrial inner membrane and can be fur-
ther processed at protease cleavage site S1 at amino acid
position 195 (NP_056375) in exon 5, which results in
short OPA1S isoforms devoid of the amino-terminal
transmembrane domain [51]. Decrease of mitochondrial
membrane potential ΔΨm results in OPA1 processing by
OMA1, which cleaves all splice-forms of OPA1L at S1 in a
ΔΨm-dependent manner [53,54]. OPA1 splice-forms 4, 6,
7, and 8 include exon 5b, which contains an additional
protease cleavage site S2 at around amino acid positions
217–223 (NP_570849) [39,51]. The mitochondrial i-AAA
protease YME1L is necessary for proteolytic cleavage of
OPA1L at S2 [39,50], and therefore generates OPA1S only
from a subset of OPA1L isoforms, which allows adjust-
ment of mitochondrial fusion (i.e. the ratio between
OPA1L and OPA1S) by gene regulation as well as protein
processing [11]. Knock-out of the mitochondrial inner
membrane protein prohibitin by targeted deletion of the
Phb2 gene leads to mitochondrial fragmentation and ab-
normal cristae structure. This involves ΔΨm–independent
processing of OPA1L to OPA1S and can be rescued by ex-
pression of non-cleavable OPA1L [56]. OPA1 is involved
in mitochondrial fusion and cristae remodeling [45]. Mito-
chondrial fusion and cristae remodeling are functionally
distinct from each other and the later correlates with
apoptotic cytochrome C release, which can be rescued by
OPA1 overexpression [46]. Initially, PARL was suggested
to be involved in OPA1L processing, cristae remodeling
and subsequent cytochrome C release [52]. However,
rhomboid proteases are not required for OPA1 processing
[57] concealing the role of PARL in apoptosis (reviewed in
[58]). Also the exact timing of cristae remodeling and
cytochrome C release is still under debate (see [59] and
references therein), as is the link between OPA1 and cris-
tae junctions [46,60,61]. The only consent to date is that
loss of OPA1 or inhibition of mitochondrial fusion by pro-
cessing the entire pool of OPA1L and subsequent frag-
mentation of the mitochondrial network triggers cell
death [39,45,50,51,53,54,56,57].
Mitochondrial quality control (MQC)
Mitochondria are vulnerable to damage of their proteins,
lipids, and mtDNA caused by various stress factors and
mitochondrial fusion allows for exchange of mtDNA [7]
and mitochondrial content between organelles in order
to attenuate or complement this damage [9]. In addition,
mitochondrial fission and selective fusion is able to sep-
arate functional from dysfunctional mitochondria; single
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by mitochondrial autophagy (see Figure 1A). A study
on pancreatic β cells has shown that mitochondrial fis-
sion generates uneven daughter units with respect to
their membrane potential [8]. Mitochondria with re-
duced membrane potential are prevented from re-fusing
to the mitochondrial network by different mechanisms
[9]. One of these mechanisms is inhibition of mitochon-
drial fusion by ΔΨm-dependent proteolytic cleavage of
OPA1L isoforms [8]. Single mitochondria that don’t fuse
anymore are subsequently targeted to mitochondrial au-
tophagy and in line with this Opa1 mutant mice show
increased autophagy in the optic nerve [62]. Conversely,
it has been shown that during starvation, mitochondria
elongate and are spared from autophagy [5]. Targeting of
mitochondria with reduced membrane potential to
autophagosomes is accomplished by the PINK1/Parkin
pathway, which is associated with familial Parkinsonism
[63]. Together, these findings document that mitochon-
drial fusion, apart from its role in exchanging mtDNA
and mitochondrial content, plays a fundamental role in
maintenance of mitochondria.
Mitochondrial network dynamics are regulated in
highly sophisticated ways by various posttranslational
modifications and proteolytic processing of the key-
proteins DRP1, MFN1 and MFN2, and OPA1 [10,11].
The carefully regulated balance of mitochondrial fusion
and fission integrates not only the mitochondrial mem-
brane potential, but also other mitochondrial, as well asFigure 1 Basic role of mitochondrial network dynamics in cell mainte
separates dysfunctional (red) from functional (blue) mitochondria. Refusion
prevented and dysfunctional mitochondria are removed and recycled by m
C), mitochondria fuse in order to protect themselves and to warrant that th
prevented, mitochondria fragment, and mitochondria signal their stressed
the organism (C).intracellular and extracellular parameters, such as redox
state, nutrition state, and toxicity load [48]. Mitochon-
dria can cope with these stress factors to certain extends
by fusing mitochondria and forming very long connected
tubular mitochondria (Figure 1B). However, if the
stressors prevail and mitochondrial damage is too high,
mitochondria signal the eukaryotic host cell to undergo
cell death by mitochondrial fragmentation, mitochon-
drial outer membrane permeabilization, and cytochrome
C release into the cytosol (Figure 1C). OPA1 is involved
in mitochondrial fusion and cytochrome C release [45],
which are functionally distinct [46], and therefore the
capability of mitochondria to fuse their inner membrane
and not fusion itself – in other words the fusion compe-
tent long isoform OPA1L – is crucial to counteract this
cell death signal cascade [56]. In line with this is the
anti-apoptotic function of hypoxia-induced gene domain
protein-1a (Higd-1a), which was shown to bind OPA1 and
in doing so to prevent proteolytic cleavage of OPA1L to
OPA1S, which in turn counteracted cytochrome C release
[64,65]. Of note, stress-induced mitochondrial hyperfusion
also relies only on the long OPA1L isoforms [48]. But still
the molecular basis for the anti-apoptotic function of
OPA1L is not fully resolved yet.
Mitochondrial outer membrane permeabilization in
order to release cytochrome C with subsequent cell death
is facilitated by various mechanisms [9,66-69]. Of note in
this context is that cardiomyocytes from Opa1 mutant
mice display delayed permeability transition pore openingnance termed mitochondrial quality control. Mitochondrial fission
of dysfunctional mitochondria to the mitochondrial network is
itochondrial autophagy (A). If a cell is stressed (yellow arrows in B and
ey are still functional (B). If the stress prevails, mitochondrial fusion is
host cell to undergo cell death thereby removing the whole cell from
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retention capacity [70]. This indicates that OPA1 –
whether the fusion competent long OPA1L isoforms or the
fusion incompetent short OPA1S isoforms is still open –
might be involved directly in mitochondrial outer mem-
brane permeabilization. Therefore OPA1 could have also aFigure 2 Principle of mitochondrial quality control with focus on OPA
dynamics. DRP1 recruitment to mitochondria is necessary and sufficient fo
equilibrium between mitochondrial fission (top) and fusion (left side). Dysfu
the mitochondrial network (not depicted for the sake of clarity). OPA1L and
membrane) are necessary and sufficient for maintaining fusion competent
proteolytic cleavage of OPA1L to OPA1S (right side). The best-characterized
mitochondrial membrane potential (ΔΨm), which leads to proteolytic cleav
various conditions enabling the integration of various parameters into mito
mitochondrial network dynamics by binding to OPA1L and thereby inhibit
membrane potential activates in the long run also the PINK1/parkin pathw
mitochondrial autophagy. OPA1L counteracts cytochrome C release and ce
(presumably together with BNIP3) is necessary to promote cytochrome C r
independent or happen in cooperation with BAX and DRP1 dependent ou
for mitochondrial autophagy and therefore could play an important role in
to recycle the whole cell by undergoing cell death.pro-cell death function besides its anti-apoptotic function
described above. BNIP3, a mitochondrial pro-apoptotic
BH3-only protein of the BCL2 family, is a direct interaction
partner of OPA1 [71], which has been associated with an
alternative mechanism of mitochondrial outer membrane
permeabilization [72]. This substantiates the pro-cell death1 function and its contribution to mitochondrial network
r mitochondrial fission. In healthy mitochondria there is a continuous
nctional mitochondria can be repaired and rescued by re-fusion to
OPA1S (together with MFN1/2 on the mitochondrial outer
mitochondria. Fusion is prevented in dysfunctional mitochondria by
example of dysfunctional mitochondria so far is dissipation of the
age of OPA1L by OMA1. OPA1 cleavage, however, occurs under
chondrial network dynamics. Higd-1a, for example, regulates
ing its proteolytic cleavage. Dissipation of the mitochondrial
ay (pink flag), which targets dysfunctional mitochondria for
ll death (black flag) and therefore acts anti-apoptotic. OPA1S
elease and cell death. This outer membrane permeabilization might be
ter membrane permeabilization (dotted line). BNIP3 is also necessary
the decision whether to remove single dysfunctional mitochondria or
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of the discussed MQC pathways and key-proteins with
focus on the role of OPA1 processing.
Discussion
It seems rather complicated to understand mitochondrial
network morphology and its significance to disease path-
ology. However, this relation might become clearer if one
recalls that the eukaryotic cell can ultimately be under-
stood only on the basis of its history [73]. Mitochondria are
descendants of a primary endosymbiosis almost 2 billion
years ago. And although mitochondria have transferred al-
most their entire genome to the nucleus of their host,
mitochondria have still preserved the power to break up
the alliance with their host by signaling cell death, some-
thing we refer to as apoptosis. Mitochondria achieve this
by releasing cytochrome C into the cytoplasm of their host
and this strategy confers an evolutionary advantage to
higher eukaryotes although, by doing so, mitochondria ex-
tinguish themselves together with their host. ThisFigure 3 Molecular model of the dual function of OPA1 in mitochond
cell death. Membrane bound OPA1L and soluble OPA1S form a complex
membrane fusion (left) and cristae organization. Proteolytic cleavage of OP
which together with BNIP3 promotes mitochondrial outer membrane (OM
bringing the mitochondrial inner membrane in proximity to the mitochond
states that are energetic favorable for membrane permeabilization.becomes more plausible if one considers that mitochon-
dria take many different intracellular and extracellular pa-
rameters into account before they decide to quit the
liaison with their host. As long as mitochondria are happy,
they continue to function normally supplying their host
with various metabolites and energy. Once the mitochon-
drial environment – in other words the host cell – is in-
appropriate, mitochondria release cytochrome C and
signal cell death. In addition, single dysfunctional or dam-
aged mitochondria can be removed from the mitochon-
drial pool by mitochondrial autophagy without any harm
for the host cell. This whole process is called MQC
(though mitochondrial ontology would be more to the
point).
One model to explain the apparently contradictory find-
ing of an anti-apoptotic as well as pro-cell death function
of OPA1 is that OPA1S supports outer membrane
permeabilization by generating membrane hemi-fusion in-
termediates between the mitochondrial inner– and outer
membrane (Figure 3). This confers a pro-cell deathrial inner membrane (IM) fusion and cytochrome C release and
that is able to attract two mitochondrial membranes to enable inner
A1L to the soluble OPA1S allows the formation of OPA1S complex,
) permeabilization, cytochrome C release, and cell death (right) by
rial outer membrane, thereby facilitating membrane hemi-fusion
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energetically favorable for membrane permeabilization.
Similar was suggested previously for hemi-fission states of
mitochondrial outer membranes [74], or hemi-fusion in-
termediates of the mitochondrial outer membrane and the
endoplasmatic reticulum [67] and it might depend on the
cell type and the nature of stress factors which mechanism
of mitochondrial outer membrane permeabilization domi-
nates. The inner membrane bound OPA1L on the other
hand binds the soluble OPA1S in order to enable mito-
chondrial inner membrane fusion, thereby preventing
inner membrane and outer membrane hemi-fusion inter-
mediates, which explains the anti-apoptotic function of
OPA1L. The pro-cell death and anti-apoptotic contribu-
tions of OPA1 might differ between cell types and depend
on the nature of the stress factor. One could speculate that
for neuronal cells DRP1 and BAX are more relevant for
outer membrane permeabilization, while in reperfusion of
cardiomyocytes outer membrane permeabilization depends
more on OPA1 and BNIP3. This model of various alterna-
tive mechanisms for outer membrane permeabilization can
explain the broad range of cell death between the two ex-
tremes necrotic- and apoptotic cell death.
Mitochondrial fusion and fission integrates not only
the mitochondrial membrane potential ΔΨm; OPA1L is
processed under various stress conditions, such as redox
state, nutrition state, and toxicity load. This implies that
mitochondrial targeting to autophagy is not only accom-
plished by the ΔΨm dependent PINK1/parkin pathway,
but also by other pathways. One such pathway could in-
volve BNIP3, because BNIP3 interacts directly with the
autophagy machinery [75] and is necessary for mito-
chondrial autophagy induced by hypoxia [76]. Interest-
ingly, BNIP3 is also highly expressed in neuronal models
of excitotoxicity [77], which is a pathological incident
that leads to neuronal cell death by excessive neuro-
transmitter stimulation, for example by stimulation of
ionotropic glutamate receptors, such as NMDA recep-
tors. Opa1 mutant mice show extensive mitochondrial
fission in RGC axons of the optic nerve head and signifi-
cantly increased NMDA receptor expression in the retina
[78]. On the other hand it was shown that excitotoxicity
results in mitochondrial hyper-fragmentation by the acti-
vation of the DRP1 fission pathway [79]. This shows that
excitotoxicity can modify the mitochondrial network and
vice versa the mitochondrial network alters components
involved in excitotoxicity and this vicious cycle likely con-
tributes to disease pathology in DOA.
Opa1 mutant mice resemble the human disease pheno-
type [22,38]. They also show reduced levels of the mito-
chondrial superoxide dismutase SOD2, which disposes
toxic superoxide into hydrogen peroxide and oxygen [78].
Increased ROS has been found in OPA1 mutant worms
and flies [80-82], and OPA1 seems to alter mitochondrialrespiration in patients with DOA [83,84]. The integration
of mitochondrial respiration and reactive oxygen species
(ROS) into the regulation of mitochondrial fission and fu-
sion, however, is still not fully resolved. Noteworthy in this
context is that OPA1L processing is inhibited by Higd-1a
and silencing of Higd-1a results in growth retardation,
cristae disorganization and loss of mtDNA [65]. Loss of
mtDNA was also described in patients with non-syndromic
DOA [85] and in patients with syndromic DOA, where loss
of mtDNA caused cytochrome C oxidase deficiency [86].
OPA1 exon 4b is thought to alter mtDNA replication and
distribution [47]. Also mtDNA deletions have been associ-
ated with OPA1 mutations in patients with non-syndromic
DOA [42] and syndromic DOA [30,31]. Conditional MFN1
and MFN2 double knock-out mice also accumulate
mtDNA deletions and show severe mtDNA depletion [87].
However, other studies challenge a direct link of OPA1 and
mtDNA deletions [88,89]. Particularly patients with severe
course of disease revealed no changes in mtDNA, for ex-
ample one patient carrying an OPA1 mutation and diag-
nosed with Behr syndrome [90], as well as the two children
that carry compound heterozygous OPA1 mutations [43].
Data on the three Opa1 mouse models are consistent with
these findings because optic nerve dysfunction and extra-
ocular impairments in these models are not linked with
mtDNA deletions or mtDNA depletion either [32,91,92].
To conclude, loss of mtDNA or mtDNA deletions can ac-
count for some but not all of the phenotypes associated
with OPA1 mutations. Although tissue specific compensa-
tion of mtDNA alterations might be an explanation [32],
mtDNA deletions and mtDNA depletion could as well be
the consequence of impaired MQC rather than the primary
cause of the disease.
Recently OPA1 was found associated to lipid droplets
of murine adipocytes and this study demonstrated that
silencing of OPA1 affects the adrenergic regulation of
the lipolysis [93]. In this context it is noteworthy that
20-month old Opa1 mutant mice showed no signs of
obesity under regular animal housing conditions, while
all animals in the control group were morbidly obese at
this age [91]. Cardiac mitochondria of Opa1 mutant
mice are also less able to oxidize lipids compared
to mitochondria of control mice [70]. Mice lacking the
protease Oma1, which has an inhibitory effect on OPA1
by processing OPA1L at S1, are obese and show decreased
fatty-acid β-oxidation compared to controls [94]. These
findings imply that OPA1 is also directly involved in the in-
tegration of the cellular metabolic state into the mitochon-
drial network and it is well established that mitochondrial
network morphology changes to adapt oxidative phosphor-
ylation to the metabolic state of the cell [6]. In accordance
to this are the alterations of oxidative phosphorylation ob-
served in patients with DOA and OPA1-silenced cells
[60,86]. Still, the knowledge on the molecular basis for the
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than ΔΨm in MQC is still vague and this topic deserves
more exploration.Conclusions
Mitochondrial fission and fusion occupies a central pos-
ition in MQC and it processes different intracellular and
extracellular parameters in order to accommodate cell
homeostasis and cell fate by the following measures:
a) Mitochondrial network morphology changes to either
a more filamentous or more fragmented state to adapt
mitochondrial function to actual energetic and metabolic
demands of the host cell. b) Fusion of dysfunctional
mitochondria to functional mitochondria can attenuate
damage to mitochondrial proteins, lipids, and mtDNA.
c) Inhibition of mitochondrial fusion targets single dys-
functional mitochondria to the mitochondrial autophagy
pathway. d) Mitochondrial fragmentation, mitochondrial
outer membrane permeabilization, and cytochrome C
release signals severely impaired host cells to undergo
cell death. According to this, mitochondrial fusion main-
tains mitochondria by attenuating mitochondrial damage
as well as by protecting from mitochondrial autophagy.
Moreover mitochondrial fusion antagonizes cell death
signaling. That is why reducing the ability of mitochon-
dria to fuse – as implied by mutations in OPA1 or dele-
tion of one OPA1 allele – compromises MQC in a way
that cells are more prone to intracellular and extra-
cellular stress factors. Interestingly this means that
dominant-negative OPA1 mutations can lead to the re-
moval of the protein coded by this dominant-negative
OPA1 allele by boosting mitochondrial autophagy. This
can phenocopy haploinsufficiency, since mutant protein
would not be detectable unless one interferes pharma-
cologically with MQC. Additionally, dominant-negative
OPA1 mutations can involve also higher mitochondrial
turnover rates as amplified mitochondrial biogenesis
may balance higher mitochondrial autophagy rates.
Impairments in MQC affect different cell types in differ-
ent individuals in a different way depending on the individ-
ual’s unique profile of intracellular and extracellular stress
factors. In other words, the heterogeneous clinical presenta-
tion of patients with DOA is caused by the individual’s
unique profile of genetic and environmental risk factors.
Then one can ask which risk factors do harm RGCs more
than other cell types? These risk factors are possibly the
same that lead to RGC death in glaucoma and genetic and
environmental risk factors that trigger glaucoma are
reviewed in numerous publications and are beyond the
scope of this article. And yet, also OPA1 polymorphisms
are discussed to be associated with certain forms of glau-
coma [95]. In this context, it is of particular interest that
glaucomatous insults trigger OPA1 cleavage, mitochondrialfission, and mitochondrial autophagy in RGC axons of the
optic nerve head in a mouse model of glaucoma [96].
To sum up, OPA1 mutations impair MQC, which is
more mitochondrial ontology than quality control, thereby
rendering cells more susceptible to stress factors. In par-
ticular RGCs are under risk but all other cell types can be
affected, too. Looking at glaucoma, there seems to be a
unique risk profile for RGCs, which is also applicable to
DOA. This brings together DOA and glaucoma.
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